Back to Research

Organization profile

Haya Therapeutics

Haya Therapeutics is a clinical-stage biotechnology company that develops precision RNA-guided therapies targeting the "dark genome" to treat chronic and age-related diseases. The company utilizes a proprietary platform to identify and drug long non-coding RNAs (lncRNAs) that act as master regulators of pathological cell states in tissues such as the heart and lungs.

Epalinges, SwitzerlandFounded 2019

Overview

1. Executive Summary (Confidence: High)

Haya Therapeutics is a pioneering precision medicine company focused on "Programming Lasting Health" through the exploration of the regulatory genome, also known as "genome dark matter".[39] Headquartered in Lausanne, Switzerland, with laboratories in San Diego, Haya utilizes a multimodal functional genomics platform to decode the 98% of the human genome that does not code for proteins.[39] Having successfully raised $65 million in Series A funding, the company is advancing its lead candidate, HTX-001, into clinical trials for heart failure, specifically targeting cardiac fibrosis.[41] By drugging long non-coding RNAs (lncRNAs) that causally drive disease, Haya aims to reprogram "sick" cell states back to healthy ones, offering a new paradigm for treating common, chronic, and age-associated conditions.[40]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.